Buprenorphine: Blending practice and research

Journal of Substance Abuse Treatment

Volumn 23, Issue 2, 2002, Pages 87-92

  Ling, Walter ^a   Smith, David ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Haight Ashbury Free Clinics   (United States)

Author keywords

Buprenorphine; Opiate dependence; Pharmacotherapy; Policy; Practice; Research

Indexed keywords

BUPRENORPHINE;

ATTITUDE; COMMUNITY; CONFERENCE PAPER; DRUG DEPENDENCE TREATMENT; DRUG SAFETY; HUMAN; OPIATE ADDICTION; PHYSICIAN; POLICY; PRIORITY JOURNAL; RESEARCH; SOCIETY;

AUSTRALIA; BUPRENORPHINE; CLINICAL TRIALS; FRANCE; HUMANS; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; SUBSTANCE ABUSE TREATMENT CENTERS; UNITED STATES;

EID: 0036768067     PISSN: 07405472     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0740-5472(02)00257-X     Document Type: Conference Paper

References (29)

1. Ali R., Riggs I., Dorlego B., Gill T., Larkins K., Mayle K., Murray T., Perrin J., Quigley A., Rysavy P., Sunjic S., Wilson C., Richards I. National buprenorphine policy. 2001;Department of Health and Aged Care, Commonwealth of Australia.
2. Amass L., Bickel W.K., Higgins S.T. Alternate-day dosing during buprenorphine treatment of opioid dependence. Life Science. 54:1994;1215-1228.
3. Auriacombe M., Franques P., Tignol J. Deaths attributable to methadone vs. buprenorphine in France [letter]. Journal of the American Medical Association. 285(1):2001;45.
4. Bickel W.K., Amass L., Crean J.P. Triple buprenorphine maintenance doses maintain opiate dependent outpatients for 72 hours with minimal withdrawal. Harris L. College on problems of drug dependence. 1994;11 NIDA Research Monograph 153, NIH#95-3883, Rockville, MD.
5. Bickel W.K., Amass L., Crean J.P., Badger G.J. Buprenorphine dosing every 1, 2, or 3 days in opioid-dependent patients. Psychopharmacology. 146(2):1999;111-118.
6. Bickel W.K., Amass L., Higgins S.T., Badger G.J., Esch R.A. Effects of adding behavioral treatment to opioid detoxification with buprenorphine. Journal of Consulting and Clinical Psychology. 65(5):1997;803-810.
7. Bouchez J., Vignau J. The French experience - the pharmacist, general practitioner and patient perspective. European Addiction Research. 4(1):1998;20-23.
8. Bridge, P., Fudala, P. J., Herbert, S., Chiang, C. N., Leiderman, D., Hill, J., Collins, J., Williford, W. O., Ling, W., & Raisch, D. (In preparation). Buprenorphine/naloxone efficacy and safety for treatment (BEST) study: public health based development of a new medication for office-based treatment of opiate dependence.
9. Fudala, P. J., Bridge, T. P., Herbert, S., Williford, W. O., Chiang, C. N., Deiderman, D., Collins, J., Raisch, D., Ajir, K., Casadonte, P., Goldsmith, J., Ling, W., Malkerneker, U., McNicholas, L., Renner, J., Stine, S., & Tusel, D. (Submitted for publication). Office-based treatment of opiate dependence: efficacy and safety of buprenorphine/naloxone sublingual tablets.
10. Huber, A., Ling, W., & Rawson, R. A. (In preparation). Steady-state pk in buprenorphine-maintained patients.
11. Jasinski D.R., Pevnick J.S., Griffith J.D. Human pharmacology and abuse potential of the analgesic buprenorphine. Archives of General Psychiatry. 35:1978;501-516.
12. Johnson R.E., Chutuape M.A., Strain E.C., Walsh S.L., Stitzer M.L., Bigelow G.E. A comparison of levomethadyl acetate, buprenorphine and methadone for opioid dependence. New England Journal of Medicine. 343:2000;1290-1295.
13. Lewis J.W. Buprenorphine. Drug and Alcohol Dependence. 14:1985;363-372.
14. Ling W., Huber A., Rawson R.A. New trends in opiate pharmacotherapy. Drug and Alcohol Review. 20:2001;79-94.
15. Lintzeris N., Clark N., Muhleisen P., Ritter A. National clinical guidelines and procedures for the use of buprenorphine in the treatment of heroin dependence. 2001;Department of Health and Aged Care, Commonwealth of Australia.
16. Mello N.K., Mendelson J.H. Buprenorphine suppresses heroin use by heroin addicts. Science. 27:1980;657-659.
17. Mello N.K., Mendelson J.H., Kuehnle J.C. Buprenorphine effects on human heroin self-administration. Journal of Pharmacology and Experimental Therapeutics. 223:1982;30-39.
18. Mendelson J., Jones R.T., Wlem S., Baggott M., Fernandez I., Melby A.K., Nath R.P. Buprenorphine and naloxone combinations: the effects of three dose rations in morphine-stabilized, opiate-dependent volunteers. Psychopharmacology. 141(1):1999;37-46.
19. Nath R.P., Upton R.A., Everhart E.T., Cheung P., Shwonek P., Jones R.T., Mendelson J.E. Buprenorphine pharmacokinetics: relative bioavailability of sublingual tablet and liquid formulations. Journal of Clinical Pharmacology. 39(6):1999;619-623.
20. Obadia Y., Perrin V. Injecting misuse of buprenorphine among French drug users. Addiction. 96:2001;267-272.
21. O'Conner P., Oliveto A. A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic. The American Journal of Medicine. 105:1998;100-105.
22. Quigley A.J., Bredemeyer D.E., Seow S.S. A case of buprenorphine abuse in Australia. Medical Journal of Australia. 140(7):1984;425-426.
23. Singh R.A., Mattoo S.K., Malhotra A., Varma V.K. Cases of buprenorphine abuse in India. Acta Psychiatrica Scandinavica. 86(1):1992;46-48.
24. Umbricht A., Montoya I.D., Hoover D.R., Demuth K.L., Chiang C.T., Preston K.L. Naltrexone shortened opioid detoxification with buprenorphine. Drug and Alcohol Dependence. 56(3):1999;181-190.
25. The Children's Health Act of 2000. H.R. 4365, Section 3502. Drug Addiction Treatment Act of 2000 (106th Congress). 2000.
26. US Department of Health and Human Services Center for Substance Abuse Treatment. (2001). Buprenorphine clinical practice guidelines: field review draft. In: L. McNicholas (Chair.), E. F. Howell (Eds.), Rockville, MD: Substance Abuse Mental Health Services Administration Center for Substance Abuse Treatment, Office of Pharmacologic and Alternative Therapies.
27. Vignau J., Brunelle E. Differences between general practitioner- and addiction centre-prescribed buprenorphine substitution therapy in France. European Addiction Research. 4(1):1998;24-28.
28. Walsh S.L., Preston K.L., Stitzer M.L., Cone E.J., Bigelow G.E. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clinical and Pharmacologic Therapeutics. 55(5):1994;569-580.
29. Walter D.S., Inturrisi C.E. Absorption, distribution, metabolism and excretion of buprenorphine in animals and humans. Cowan A., Lewis J.W. Buprenorphine: combining drug abuse with a unique opioid. 1995;113-135 Wiley-Liss Inc, New York.